Functional, Anatomical, and Prognostic Correlates of Coronary Flow Velocity Reserve During Stress Echocardiography.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
05 11 2019
Historique:
received: 17 01 2019
revised: 08 08 2019
accepted: 12 08 2019
entrez: 2 11 2019
pubmed: 2 11 2019
medline: 23 5 2020
Statut: ppublish

Résumé

The assessment of coronary flow velocity reserve (CFVR) in left anterior descending coronary artery (LAD) expands the risk stratification potential of stress echocardiography (SE) based on stress-induced regional wall motion abnormalities (RWMA). The purpose of this study was to assess the feasibility and functional correlates of CFVR. This prospective, observational, multicenter study initially screened 3,410 patients (2,061 [60%] male; age 63 ± 11 years; ejection fraction 61 ± 9%) with known or suspected coronary artery disease and/or heart failure. All patients underwent SE (exercise, n = 1,288; vasodilator, n = 1,860; dobutamine, n = 262) based on new or worsening RWMA in 20 accredited laboratories of 8 countries. CFVR was calculated as the stress/rest ratio of diastolic peak flow velocity pulsed-Doppler assessment of LAD flow. A subset of 1,867 patients was followed up. The success rate for CFVR on LAD was 3,002 of 3,410 (feasibility = 88%). Reduced (≤2.0) CFVR was found in 896 of 3,002 (30%) patients. At multivariable logistic regression analysis, inducible RWMA (odds ratio [OR]: 6.5; 95% confidence interval [CI]: 4.9 to 8.5; p < 0.01), abnormal left ventricular contractile reserve (OR: 3.4; 95% CI: 2.7 to 4.2; p < 0.01), and B-lines (OR: 1.5; 95% CI: 1.1 to 1.9; p = 0.01) were associated with reduced CFVR. During a median follow-up time of 16 months, 218 events occurred. RWMA (hazard ratio: 3.8; 95% CI: 2.3 to 6.3; p < 0.001) and reduced CFVR (hazard ratio: 1.5; 95% CI: 1.1 to 2.2; p = 0.009) were independently associated with adverse outcome. CFVR is feasible with all SE protocols. Reduced CFVR is often accompanied by RWMA, abnormal LVCR, and pulmonary congestion during stress, and shows independent value over RWMA in predicting an adverse outcome.

Sections du résumé

BACKGROUND
The assessment of coronary flow velocity reserve (CFVR) in left anterior descending coronary artery (LAD) expands the risk stratification potential of stress echocardiography (SE) based on stress-induced regional wall motion abnormalities (RWMA).
OBJECTIVES
The purpose of this study was to assess the feasibility and functional correlates of CFVR.
METHODS
This prospective, observational, multicenter study initially screened 3,410 patients (2,061 [60%] male; age 63 ± 11 years; ejection fraction 61 ± 9%) with known or suspected coronary artery disease and/or heart failure. All patients underwent SE (exercise, n = 1,288; vasodilator, n = 1,860; dobutamine, n = 262) based on new or worsening RWMA in 20 accredited laboratories of 8 countries. CFVR was calculated as the stress/rest ratio of diastolic peak flow velocity pulsed-Doppler assessment of LAD flow. A subset of 1,867 patients was followed up.
RESULTS
The success rate for CFVR on LAD was 3,002 of 3,410 (feasibility = 88%). Reduced (≤2.0) CFVR was found in 896 of 3,002 (30%) patients. At multivariable logistic regression analysis, inducible RWMA (odds ratio [OR]: 6.5; 95% confidence interval [CI]: 4.9 to 8.5; p < 0.01), abnormal left ventricular contractile reserve (OR: 3.4; 95% CI: 2.7 to 4.2; p < 0.01), and B-lines (OR: 1.5; 95% CI: 1.1 to 1.9; p = 0.01) were associated with reduced CFVR. During a median follow-up time of 16 months, 218 events occurred. RWMA (hazard ratio: 3.8; 95% CI: 2.3 to 6.3; p < 0.001) and reduced CFVR (hazard ratio: 1.5; 95% CI: 1.1 to 2.2; p = 0.009) were independently associated with adverse outcome.
CONCLUSIONS
CFVR is feasible with all SE protocols. Reduced CFVR is often accompanied by RWMA, abnormal LVCR, and pulmonary congestion during stress, and shows independent value over RWMA in predicting an adverse outcome.

Identifiants

pubmed: 31672185
pii: S0735-1097(19)37650-8
doi: 10.1016/j.jacc.2019.08.1046
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2278-2291

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Quirino Ciampi (Q)

Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy.

Angela Zagatina (A)

Cardiology Department, Saint Petersburg University Clinic, Saint Petersburg, Russian Federation.

Lauro Cortigiani (L)

Cardiology Department, San Luca Hospital, Lucca, Italy.

Nicola Gaibazzi (N)

Cardiology Department, Parma University Hospital, Parma, Italy.

Clarissa Borguezan Daros (C)

Cardiology Division, Hospital São José, Criciuma, Brazil.

Nadezhda Zhuravskaya (N)

Cardiology Department, Saint Petersburg University Clinic, Saint Petersburg, Russian Federation.

Karina Wierzbowska-Drabik (K)

Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

Jaroslaw D Kasprzak (JD)

Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

José Luis de Castro E Silva Pretto (JL)

Hospital Sao Vicente de Paulo e Hospital de Cidade, Passo Fundo, Brazil.

Antonello D'Andrea (A)

Cardiology Department, Echocardiography Lab and Rehabilitation Unit, Monaldi Hospital, Second University of Naples, Naples, Italy.

Ana Djordjevic-Dikic (A)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Ines Monte (I)

Cardio-Thorax-Vascular Department, Echocardiography Lab, "Policlinico Vittorio Emanuele," Catania University, Catania, Italy.

Iana Simova (I)

Head of Cardiology Department, Acibadem City Clinic Cardiovascular Center, University Hospital, Sofia, Bulgaria.

Alla Boshchenko (A)

Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation.

Rodolfo Citro (R)

Cardiology Department and Echocardiography Lab, University Hospital "San Giovanni di Dio e Ruggi d'Aragona," Salerno, Italy.

Miguel Amor (M)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.

Pablo Martin Merlo (PM)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Claudio Dodi (C)

Casa di Cura Figlie di San Camillo, Cremona, Italy.

Fausto Rigo (F)

Cardiology Department, Ospedale dell'Angelo Mestre-Venice, Venice, Italy.

Suzana Gligorova (S)

Cardiology Division Ospedale Casilino, Roma, Italy.

Milica Dekleva (M)

Clinical Cardiology Department, Clinical Hospital Zvezdara, Medical School, University of Belgrade, Belgrade, Serbia.

Sergio Severino (S)

Cardiology Department, Coronary Care Unit, Monaldi Hospital, Second University of Naples, Naples, Italy.

Fabio Lattanzi (F)

Cardiothoracic Department, University of Pisa, Pisa, Italy.

Maria Chiara Scali (MC)

Cardiothoracic Department, University of Pisa, Pisa, Italy.

Alexander Vrublevsky (A)

Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation.

Marco A R Torres (MAR)

Hospital de Clinicas de Porto Alegre-Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Alessandro Salustri (A)

Non-invasive Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Hugo Rodrìguez-Zanella (H)

Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.

Fabio Marco Costantino (FM)

Cardiology Department, San Carlo Hospital, Potenza, Italy.

Albert Varga (A)

Institute of Family Medicine, University of Szeged, Szeged, Hungary.

Eduardo Bossone (E)

Azienda Ospedaliera Rilevanza Nazionale A. Cardarelli Hospital, Naples, Italy.

Paolo Colonna (P)

Cardiology Hospital, Policlinico of Bari, Bari, Italy.

Michele De Nes (M)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Marco Paterni (M)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Clara Carpeggiani (C)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Jorge Lowenstein (J)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Dario Gregori (D)

Biostatistics, Epidemiology and Public Health Unit, Padova University, Padova, Italy.

Eugenio Picano (E)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy. Electronic address: picano@ifc.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH